Idiopathic pulmonary fibrosis and pulmonary hypertension - Connecting the dots

被引:162
作者
Nathan, Steven D.
Noble, Paul W.
Tuder, Rubin M.
机构
[1] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, Inova Heart & Vasc Inst, Falls Church, VA 22042 USA
[2] Duke Univ, Div Pulm Allergy & Crit Care Med, Durham, NC USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
关键词
pulmonary fibrosis; hypertension; pulmonary; function tests; cytokines;
D O I
10.1164/rccm.200608-1153CC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and a course that is unpredictable. Pulmonary hypertension may complicate the course of IPF and potentially impact prognosis. There are multiple factors that might influence the onset and severity of pulmonary hypertension in IPF. The relationship between the physiologic and pathobiologic manifestations of the progressive fibrotic process and interceding pulmonary hypertension has not been well defined. This article serves to explore these relationships and to hypothesize about the possible linkage between these entities. From a prognostic standpoint, recent evidence suggests this to be important to assess for pulmonary hypertension in patients with IPF. The appropriate triggers for evaluating for pulmonary hypertension and the best method of detection require further study. Despite the relative ease of noninvasive methods, such as echocardiography, right-heart catheterization remains the best diagnostic test. The appeal of pulmonary hypertension in IPF is that it may be an enticing therapeutic target in a disease that otherwise does not have any proven effective therapies. Which agent(s) might be useful and when they should be implemented mandate the appropriate studies being performed. Some of the data presented in this article have previously been reported in abstract form only.
引用
收藏
页码:875 / 880
页数:6
相关论文
共 54 条
[1]   Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease [J].
Arcasoy, SM ;
Christie, JD ;
Ferrari, VA ;
Sutton, MS ;
Zisman, DA ;
Blumenthal, NP ;
Pochettino, A ;
Kotloff, RM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :735-740
[2]  
Ask Kjetil, 2006, Proc Am Thorac Soc, V3, P389, DOI 10.1513/pats.200602-021TK
[3]   Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis [J].
Bjoraker, JA ;
Ryu, JH ;
Edwin, MK ;
Myers, JL ;
Tazelaar, HD ;
Schroeder, DR ;
Offord, KP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (01) :199-203
[4]   Endothelial dysfunction in pulmonary hypertension [J].
Budhiraja, R ;
Tuder, RM ;
Hassoun, PM .
CIRCULATION, 2004, 109 (02) :159-165
[5]   CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling [J].
Burdick, MD ;
Murray, LA ;
Keane, MP ;
Xue, YY ;
Zisman, DA ;
Belperio, JA ;
Strieter, RM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (03) :261-268
[6]   Eicosanoids: mediators and therapeutic targets in fibrotic lung disease [J].
Charbeneau, RP ;
Peters-Golden, M .
CLINICAL SCIENCE, 2005, 108 (06) :479-491
[7]   Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
King, TE ;
Bartelson, BB ;
Vourlekis, JS ;
Schwarz, MI ;
Brown, KK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542
[8]   Pigment epithelium - derived factor in idiopathic pulmonary fibrosis - A role in aberrant angiogenesis [J].
Cosgrove, GP ;
Brown, KK ;
Schiemann, WP ;
Serls, AE ;
Parr, JE ;
Geraci, MW ;
Schwarz, MI ;
Cool, CD ;
Worthen, GS .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (03) :242-251
[9]   Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis [J].
Ebina, M ;
Shimizukawa, M ;
Shibata, N ;
Kimura, Y ;
Suzuki, T ;
Endo, M ;
Sasano, H ;
Kondo, T ;
Nukiwa, T .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (11) :1203-1208
[10]   MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].
ECHT, DS ;
LIEBSON, PR ;
MITCHELL, LB ;
PETERS, RW ;
OBIASMANNO, D ;
BARKER, AH ;
ARENSBERG, D ;
BAKER, A ;
FRIEDMAN, L ;
GREENE, HL ;
HUTHER, ML ;
RICHARDSON, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788